Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
May 22, 2024 08:00 ET
|
Avadel Pharmaceuticals plc
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in...
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
May 21, 2024 07:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the...
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 08, 2024 07:00 ET
|
Avadel Pharmaceuticals plc
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients...
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
May 01, 2024 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it...
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
April 01, 2024 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
March 05, 2024 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Issues Statement On Patent Litigation
March 04, 2024 15:37 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the...
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 04, 2024 06:30 ET
|
Avadel Pharmaceuticals plc
-- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ -- -- As of January 31st, greater than 2,200 patients enrolled in...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4
February 26, 2024 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...